LIVIVO - Search results -

Search results

Result 1 - 10 of total 46

Search options

Article: Menopausale Hormontherapie: Wie und wie lange für gesunde Frauen über 65?

Wiegratz, Inka

Therapeutische Umschau. Revue therapeutique

2021 Volume 78, Issue 8, Page(s) 457–464

Abstract: MHT: How and how long in healthy women above 65? ...

Title translation	MHT: How and how long in healthy women above 65?
Abstract	MHT: How and how long in healthy women above 65?
MeSH term(s)	Aged ; Estrogen Replacement Therapy ; Estrogens ; Female ; Humans ; Menopause ; Postmenopause ; Quality of Life
Chemical Substances	Estrogens
Language	German
Publishing date	2021-09-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	82044-1
ISSN	1664-2864 ; 0040-5930
ISSN (online)	1664-2864
ISSN	0040-5930
DOI	10.1024/0040-5930/a001297
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.180: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Langzyklus

Wiegratz, Inka / Kuhl, Herbert

27 Tabellen ; [weniger Menstruationen - weniger Menstruationsbeschwerden - weniger zyklusabhängige Erkrankungen]

2010

Author's details	Inka Wiegratz und Herbert Kuhl
Keywords	Menstruationszyklus ; Verlängerung ; Ovulationshemmer
Subject	Antibabypille ; Pille ; Orale Empfängnisverhütung ; Orale Kontrazeption ; Genitalzyklus ; Ovarialzyklus ; Weiblicher Zyklus
Language	German
Size	VIII, 92 S. : graph. Darst., 27 cm
Publisher	Thieme
Publishing place	Stuttgart ; New York, NY
Publishing country	Germany
Document type	Book
Note	Literaturangaben
HBZ-ID	HT016432814
ISBN	978-3-13-153301-2 ; 3-13-153301-3
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2010 A 3480	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Wirkung zweier niedrig dosierter, oraler Kontrazeptiva auf verschiedene Fettstoffwechselparameter bei 50 Frauen

Wiegratz, Inka

1992

Author's details	vorgelegt von Inka Wiegratz
Size	110 S. : graph. Darst.
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Frankfurt am Main, Univ., Diss., 1992
HBZ-ID	HT004434823
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
93 D 374	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The drospirenone (DRSP)-only pill: clinical implications in the daily use.

Kubba, Ali / Gemzell-Danielsson, Kristina / Palacios, Santiago / Wiegratz, Inka / Grandi, Giovanni / Colli, Enrico / Regidor, Pedro Antonio

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

2023 Volume 28, Issue 1, Page(s) 36–43

Abstract: Objectives: Progestins used in contraception are either components of combined hormonal contraceptives or are used as a single active ingredient. Progestins are highly effective in long-term contraception and have a very good safety profile with very ... ...

Abstract	Objectives: Progestins used in contraception are either components of combined hormonal contraceptives or are used as a single active ingredient. Progestins are highly effective in long-term contraception and have a very good safety profile with very few contraindications. Methods: An oestrogen-free ovulation inhibitor POP has been authorised in the USA and the EU. It contains 4 mg of drospirenone (DRSP). The hormone administration regimen of 24 days followed by a 4-day hormone-free period was chosen to improve bleeding control and to maintain oestradiol concentrations at early follicular- phase levels, preventing oestrogen deficiency. Results: Clinical trials have demonstrated high contraceptive effectiveness, a very low risk of cardiovascular risk events and a favourable bleeding pattern. Due to the long half-life of DRSP (30-34 h), the effectiveness is maintained even in case of a forgotten pill on a single occasion. Studies involving deliberate 4 days in one cycle 24-hour delays in taking a pill have demonstrated that ovulation inhibition is maintained if a single pill is missed. Conclusions: This review article will describe the clinical impact in the daily use of the 4 mg DRSP only pill and the resulting data on the effectiveness and safety of this hormonal contraceptive.
MeSH term(s)	Female ; Humans ; Progestins ; Androstenes/adverse effects ; Contraception/methods ; Estradiol ; Contraceptive Agents ; Contraceptives, Oral, Combined
Chemical Substances	Progestins ; drospirenone (N295J34A25) ; Androstenes ; Estradiol (4TI98Z838E) ; Contraceptive Agents ; Contraceptives, Oral, Combined
Language	English
Publishing date	2023-02-01
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	1397560-2
ISSN	1473-0782 ; 1362-5187
ISSN (online)	1473-0782
ISSN	1362-5187
DOI	10.1080/13625187.2022.2164186
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4819: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The risk of thromboembolism and use of combined oral contraceptives: a comment.

Birkhäuser, Martin / Böttcher, Bettina / Germeyer, Ariane / Hadji, Peyman / Imthurn, Bruno / Mueck, Alfred O / Neulen, Joseph / Stute, Petra / Thaler, Christian J / Wiegratz, Inka / Wildt, Ludwig

BJOG : an international journal of obstetrics and gynaecology

2023 Volume 130, Issue 7, Page(s) 844–845

MeSH term(s)	Female ; Humans ; Contraceptives, Oral, Combined/adverse effects ; Venous Thromboembolism/chemically induced ; Risk Factors ; Contraceptives, Oral, Hormonal/adverse effects
Chemical Substances	Contraceptives, Oral, Combined ; Contraceptives, Oral, Hormonal
Language	English
Publishing date	2023-03-08
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	2000931-8
ISSN	1471-0528 ; 0306-5456 ; 1470-0328
ISSN (online)	1471-0528
ISSN	0306-5456 ; 1470-0328
DOI	10.1111/1471-0528.17434
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um I Zs.121: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.

Sydow, Peter / Gmeinwieser, Norbert / Pribbernow, Katrin / Keck, Christoph / Wiegratz, Inka

Reproductive biology and endocrinology : RB&E

2020 Volume 18, Issue 1, Page(s) 54

Abstract: Background: The use of recombinant human follicle-stimulating hormone (r-hFSH) in ovarian stimulation protocols for infertility treatment in assisted reproductive technology (ART) clinical practice is well established. More recent advancements include ... ...

Abstract	Background: The use of recombinant human follicle-stimulating hormone (r-hFSH) in ovarian stimulation protocols for infertility treatment in assisted reproductive technology (ART) clinical practice is well established. More recent advancements include the availability of biosimilar r-hFSH products, which expand the choices available to healthcare practitioners and patients. Better understanding of how such a product contributes to routine clinical practice is valuable to help prescribers make informed treatment choices. The objective of this study was to examine the effectiveness and safety of ovarian stimulation (OS) with follitropin alfa (Ovaleap®) for routine IVF or intracytoplasmic sperm injection treatment in gonadotropin-releasing hormone (GnRH) antagonist cycles in real-world ART clinical practice. Methods: This non-interventional, multicenter, prospective study was initiated in 34 specialized reproductive medicine centers in Germany. Eligible women were 18-40 years old with a body mass index < 30 kg/m Result(s): Of 507 women screened, 463 received at least 1 dose of Ovaleap® and 439 had Visit 2 data (per protocol population; PPP). The mean(±SD) number of retrieved oocytes was 11.8 ± 7.2 (PPP). The CPR among women with documented embryo transfer was 41.3% (158/383), resulting in a live birth delivery rate of 31.6% (138/437) among PPP patients with available follow-up information. Overall, 8.6% (40/463) of women reported ≥1 adverse drug reaction. Ovarian hyperstimulation syndrome occurred in 23 (5.0%) patients, rated mild in 14 (3.0%), moderate in 8 (1.7%), and severe in 1 (0.2%). Patients reported high user satisfaction and high convenience with use of the Ovaleap® pen. Conclusion: The effectiveness and safety of OS with Ovaleap® in a GnRH antagonist protocol were extended to real-world ART clinical practice for the first time. Trial registration: Registered on 22 June 2016 (retrospectively registered) at ClinicalTrials.gov (NCT02809989).
MeSH term(s)	Adult ; Birth Rate ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Follicle Stimulating Hormone, Human/adverse effects ; Follicle Stimulating Hormone, Human/therapeutic use ; Germany/epidemiology ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Hormone Antagonists/therapeutic use ; Humans ; Infant, Newborn ; Infertility/epidemiology ; Infertility/therapy ; Male ; Ovulation Induction/adverse effects ; Ovulation Induction/methods ; Patient Satisfaction/statistics & numerical data ; Pregnancy ; Pregnancy Rate ; Prospective Studies ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Reproductive Techniques, Assisted ; Retrospective Studies ; Treatment Outcome
Chemical Substances	Follicle Stimulating Hormone, Human ; Hormone Antagonists ; Recombinant Proteins ; follitropin alfa ; Gonadotropin-Releasing Hormone (33515-09-2)
Language	English
Publishing date	2020-05-26
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study
ISSN	1477-7827
ISSN (online)	1477-7827
DOI	10.1186/s12958-020-00610-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book: Langzyklus

Wiegratz, Inka

2010

Author's details	Inka Wiegratz und Herbert Kuhl
MeSH term(s)	Menstrual Cycle/drug effects ; Contraceptives, Oral, Hormonal
Language	German
Size	viii, 92 p. :, ill.
Publisher	Thieme
Publishing place	Stuttgart
Document type	Book
ISBN	9783131533012 ; 3131533013
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.

Hadji, Peyman / Neulen, Joseph / Schaudig, Katrin / Schwenkhagen, Anneliese / Grimmbacher, Stefanie / Wiegratz, Inka

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

2020 Volume 36, Issue 6, Page(s) 513–520

Abstract: The objective was to assess efficacy and safety of a combined oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in an extended-cycle vs. a conventional-cycle regimen. This first European randomized, active controlled, open, ... ...

Abstract	The objective was to assess efficacy and safety of a combined oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in an extended-cycle vs. a conventional-cycle regimen. This first European randomized, active controlled, open, prospective, parallel-group trial was conducted in 48 German gynecological centers. 1,314 healthy, sexually active women aged 18-35 years were randomized. With an unadjusted PI of 0.483 (upper 95% CI: 1.237), the extended-cycle regimen fulfilled the contraceptive efficacy of EE/LNG, the requirements of the European Medicines Agency. The mean total number of bleeding days per year was significantly lower in the extended-cycle vs. the conventional-cycle regimen. Analyses of bleeding patterns showed a reduced total number of bleeding/spotting days per year in the extended-cycle vs. the conventional-cycle regimen. Cycle-associated complaints and AE were comparable in both groups. Both regimens were very well accepted. The extended-cycle regimen of EE/LNG was effective and well tolerated resulting in a lower number of bleeding days and a favorable bleeding pattern compared to the conventional-cycle regimen.
MeSH term(s)	Adolescent ; Adult ; Contraceptives, Oral, Combined/administration & dosage ; Contraceptives, Oral, Combined/adverse effects ; Drug Administration Schedule ; Drug Combinations ; Ethinyl Estradiol/administration & dosage ; Ethinyl Estradiol/adverse effects ; Female ; Germany ; Humans ; Levonorgestrel/administration & dosage ; Levonorgestrel/adverse effects ; Menstrual Cycle/drug effects ; Menstrual Cycle/physiology ; Menstruation/drug effects ; Menstruation/physiology ; Treatment Outcome ; Young Adult
Chemical Substances	Contraceptives, Oral, Combined ; Drug Combinations ; ethinyl estradiol, levonorgestrel drug combination ; Ethinyl Estradiol (423D2T571U) ; Levonorgestrel (5W7SIA7YZW)
Language	English
Publishing date	2020-02-16
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	639237-4
ISSN	1473-0766 ; 0951-3590
ISSN (online)	1473-0766
ISSN	0951-3590
DOI	10.1080/09513590.2020.1725963
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2284: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 608: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hormonal contraception--what kind, when, and for whom?

Wiegratz, Inka / Thaler, Christian J

Deutsches Arzteblatt international

2011 Volume 108, Issue 28-29, Page(s) 495–505; quiz 506

Abstract: Background: In Germany today, one-third of the 20 million women of child-bearing age use combined oral contraceptives (COCs). In this article, we summarize the current knowledge of the mode of action, wanted and unwanted side effects, and long-term ... ...

Abstract	Background: In Germany today, one-third of the 20 million women of child-bearing age use combined oral contraceptives (COCs). In this article, we summarize the current knowledge of the mode of action, wanted and unwanted side effects, and long-term risks of COCs. The levonorgestrel intrauterine device (IUD) and long-acting injectable or implantable monophasic progestogen preparations offer comparable contraceptive efficacy to COCs. Nonetheless, they are less frequently used in Germany than COCs, because of their propensity to cause breakthrough bleeding. Method: Selective review of the literature. Results: COCs suppress gonadotropin secretion and thereby inhibit follicular maturation and ovulation. Their correct use is associated with 0.3 pregnancies per 100 women per year, their typical use, with 1 pregnancy per 100 women per year (Pearl index). COCs have effects on the cardiovascular and hemostatic systems as well as on lipid and carbohydrate metabolism. When given in the presence of specific risk factors, they significantly increase the likelihood of cardiovascular disease and thromboembolism. Women with persistent human papilloma virus (HPV) infection who take COCs are at increased risk of developing invasive cervical cancer. On the other hand, COCs lower the cumulative incidence of endometrial and ovarian cancer by 30% to 50%, and that of colorectal cancer by 20% to 30%. Other malignancies seem to be unaffected by COC use. Conclusion: As long as personal and familial risk factors are carefully considered, COCs constitute a safe, reversible, and well-tolerated method of contraception.
MeSH term(s)	Cardiovascular Diseases/chemically induced ; Contraceptives, Oral, Combined/administration & dosage ; Contraceptives, Oral, Combined/adverse effects ; Contraceptives, Oral, Hormonal/administration & dosage ; Contraceptives, Oral, Hormonal/adverse effects ; Drug Implants ; Drug-Related Side Effects and Adverse Reactions ; Female ; Germany ; Humans ; Injections, Intramuscular ; Intrauterine Devices, Medicated ; Levonorgestrel ; Papillomavirus Infections/complications ; Pregnancy ; Pregnancy, Unwanted ; Progesterone Congeners/administration & dosage ; Progesterone Congeners/adverse effects ; Risk Factors ; Thromboembolism/chemically induced ; Uterine Cervical Neoplasms/chemically induced
Chemical Substances	Contraceptives, Oral, Combined ; Contraceptives, Oral, Hormonal ; Drug Implants ; Progesterone Congeners ; Levonorgestrel (5W7SIA7YZW)
Language	English
Publishing date	2011-07-18
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2406159-1
ISSN	1866-0452 ; 1866-0452
ISSN (online)	1866-0452
ISSN	1866-0452
DOI	10.3238/arztebl.2011.0495
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

Römer, Thomas / Bitzer, Johannes / Egarter, Christian / Hadji, Peyman / Kiechle, Marion / Kramer, Heike / Oppelt, Patricia G / Peters, Klaus / Stute, Petra / Schaudig, Katrin / Wiegratz, Inka / Regidor, Pedro-Antonio

Geburtshilfe und Frauenheilkunde

2021 Volume 81, Issue 9, Page(s) 1021–1030

Abstract: Hormonal contraceptives are an effective and safe method for preventing pregnancy. Progestins used in contraception are either components of combined hormonal contraceptives (tablets, patches or vaginal rings) or are used as a single active ingredient in ...

Abstract	Hormonal contraceptives are an effective and safe method for preventing pregnancy. Progestins used in contraception are either components of combined hormonal contraceptives (tablets, patches or vaginal rings) or are used as a single active ingredient in progestin mono-preparations (the progestin-only pill (POP), implants, intrauterine systems or depot preparations). Progestins are highly effective in long-term contraception when used properly, and have a very good safety profile with very few contraindications. A new oestrogen-free ovulation inhibitor (POP) has recently been authorised in the USA and the EU. This progestin mono-preparation contains 4 mg of drospirenone (DRSP), which has anti-gonadotropic, anti-mineralocorticoidic and anti-androgenic properties. The hormone administration regimen of 24 days followed by a 4-day hormone-free period was chosen to improve bleeding control and to maintain oestradiol concentrations at early follicular-phase levels, preventing oestrogen deficiency. Clinical trials have demonstrated a high contraceptive effectiveness, a very low risk of cardiovascular side effects and a favourable menstrual bleeding pattern. Due to the long half-life of DRSP (30 - 34 hours), the effectiveness of the preparation is maintained even if a woman forgets to take a pill on a single occasion. Studies involving deliberate 24-hour delays in taking a pill have demonstrated that ovulation inhibition is maintained if a single pill is missed. Following a summary of the current status of oestrogen-free contraception, this review article will describe the clinical development programme of the 4 mg DRSP mono-preparation and the resulting data on the effectiveness and safety of this new oestrogen-free oral hormonal contraceptive.
Language	English
Publishing date	2021-06-14
Publishing country	Germany
Document type	Journal Article
ZDB-ID	80111-2
ISSN	1438-8804 ; 0016-5751 ; 1615-3359
ISSN (online)	1438-8804
ISSN	0016-5751 ; 1615-3359
DOI	10.1055/a-1471-4408
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um I Zs.190: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 655: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito